ACC/AHA/NHLBI clinical advisory on the use and safety of statins
ACC/AHA/NHLBI clinical advisory on the use and safety of statins
复制标题
DOI：
10.1161/01.cir.0000032466.44170.44
复制
发表时间：
2002-08-20
期刊：
影响因子：
37.8
通讯作者：
Lenfant, C
中科院分区：
文献类型：
--
作者：
Pasternak, RC;Smith, SC;Lenfant, C
2001年8月8日，西立伐他汀（Baycol）的生产商与美国食品药品监督管理局（FDA）达成协议，自愿从美国市场撤回西立伐他汀（Baycol），这引起了医生和患者对降胆固醇类药物HMG CoA还原酶抑制剂（通常称为“他汀类药物”）安全性的担忧。本美国心脏病学会/美国心脏协会/国家心肺血液研究所（ACC/AHA/NHLBI）临床咨询旨在为专业人员总结目前对他汀类药物使用的理解，重点关注肌病，并提供适当使用他汀类药物的最新建议，包括他汀类药物治疗的注意事项，禁忌症和安全性监测。其目的不是阻止他汀类药物的适当使用，他汀类药物在适当选择的患者中具有挽救生命的潜力，特别是那些患有冠心病（CHD）的患者和其他冠心病高风险患者。包括最近由FDA汇编的肌病信息，来自临床试验的信息，以及最近发布的国家胆固醇教育计划（NCEP）成人治疗小组III（ATP III）报告的摘要（1）。
The voluntary withdrawal of cerivastatin (Baycol) from the US market on August 8, 2001, by the manufacturer, in agreement with the Food and Drug Administration (FDA), has prompted concern on the part of physicians and patients regarding the safety of the cholesterol-lowering class of drugs called HMG CoA reductase inhibitors, more commonly known as “statins.” This American College of Cardiology/American Heart Association/National Heart, Lung and Blood Institute (ACC/AHA/NHLBI) Clinical Advisory is intended to summarize for professionals the current understanding of statin use, focused on myopathy, and to provide updated recommendations for the appropriate use of statins, including cautions, contraindications, and safety monitoring for statin therapy. Its purpose is not to discourage the appropriate use of statins, which have life-saving potential in properly selected patients, particularly those with established coronary heart disease (CHD) and others at high risk for developing CHD. Included are recent myopathy information compiled by the FDA, information from clinical trials, and summaries from the recently released report of the Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program (NCEP)(1).